EAU Upgrades Aquablation to Strong Surgical Recommendation for BPH
Event summary
- EAU guidelines now strongly recommend Aquablation therapy as an alternative to TURP for moderate-to-severe BPH.
- Upgrade based on clinical evidence from WATER, WATER II, and WATER III trials.
- Aquablation recognized for durable symptom relief and preservation of ejaculatory function.
- EAU guidelines are among the most rigorous and influential in global urology.
The big picture
The EAU's strong recommendation for Aquablation marks a pivotal shift in BPH treatment, validating PROCEPT's technology against the long-standing TURP standard. This upgrade aligns with broader trends in urology toward minimally invasive, robotics-assisted procedures that prioritize patient outcomes. With growing clinical evidence and regulatory support, Aquablation is positioned to capture significant market share in a $4B+ global BPH treatment space.
What we're watching
- Clinical Adoption
- How the EAU upgrade will accelerate Aquablation's adoption in European markets.
- Competitive Positioning
- Whether PROCEPT can leverage this endorsement to challenge TURP's dominance.
- Regulatory Expansion
- The pace at which other health bodies, like NICE, formalize Aquablation's use.